share print

A healthcare professional

If you are a healthcare professional, this page is for you

We dream, dare, share the future with you.
We dream to create opportunities and innovate, by daring to push the boundaries of medicine in women’s health and endocrinology.  Knowledge sharing and collaboration are fundamental to innovation - that is why we listen to your needs and work together on all aspects of treatments from the early stages of clinical trials to the availability of our treatments on the market.

As a healthcare professional, you are on the frontline, counseling, treating patients, or prescribing medicines on a daily basis – your needs drive our actions…

To find out in more detail what we do, and how we collaborate with healthcare professionals, please go to the HRA Pharma way page.

Further useful information can be found on the following HRA Pharma pages:
HRA Pharma clinical trials  
Our research & innovation model 
• Our pipelines: women's health, endocrinology, cell therapy
Our partnerships

Learn more information on our products in women’s health and endocrinology.

HRA Pharma at your service: on matters of women’s health

It is estimated that approximately 100 million women worldwide take the contraceptive pill, with healthcare professionals – notably physicians, pharmacists and family planning teams – being the first port of call for many.*

We are also aware of the key role pharmacists play in providing access to emergency contraception.

HRA Pharma teams are ready to answer any questions you may have about our products.
If you have a particular question or would like information concerning one of our products, please contact us.
We are also keen to keep you updated on HRA Pharma news items and communicate any product updates or clinical trial results.

In agreement with the European Medicines Agency (EMA), HRA Pharma has decided to establish a pregnancy registry to collect information on any pregnancy exposed to ellaOne®, e.g. unrecognized pregnancy before intake or treatment failure. We would be grateful if you could provide us with information about pregnancies that were exposed to ellaOne® or pregnancies that happened despite the use of ellaOne®. Your help will build the knowledge we need for safe use of ellaOne®.
Access pregnancy registry

Discover our complete product portfolio in women’s health.

*http://www.princeton.edu/~achaney/tmve/wiki100k/docs/Combined_oral_contraceptive_pill.html

On matters of endocrinology

We focus on the management of severe adrenal diseases and Cushing’s syndrome. We are active pioneers in these specific therapeutic areas, which are greatly underserved.

Discover our complete product portfolio in endocrinology.

About 30 million* people living in the European Union (EU) suffer from a rare disease. 
*Rare Disease Day 2014 – twelve new orphan medicines available to patients over the past year. European Medicine Agency website. 

With LYSOSAFE® Service 

LYSOSAFE® Service is a completely free service**, which includes shipping samples to a unique centralized bioanalytical center, testing the samples following standard protocols by a GC/MS assay (gas chromatography / mass spectrometry) and returning the results within a few days. Please don’t hesitate to contact us if you have a particular question concerning LYSOSAFE® Service.

** Free of charge transport in Europe only

closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?